Abstract
Influenza B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S. 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from 2016/17–2019/20 by combining B/Yamagata prevalence data with model-based estimates of disease burden prevented by vaccination against all influenza B viruses. B/Yamagata comprised approximately 16–22% of positive virus specimens in 2016/17 and 2017/18, compared to 1% in 2018/19 and 2019/20. Across all seasons, we estimated that vaccination against B/Yamagata prevented 4.15 million illnesses, 58,500 hospitalizations, and 4,070 deaths, and that 22.9 million B/Yamagata-associated illnesses, 340,000 hospitalizations, and 25,100 deaths would have occurred without vaccination. Vaccination prevented the most B/Yamagata hospitalizations among adults ≥65 years but prevented the greatest percentage of B/Yamagata hospitalizations among children 6 months–4 years. Our results may help assess the potential impact if B/Yamagata were to recirculate in the absence of vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data were the result of secondary analyses. The Centers for Disease Control and Prevention determined that the study met the requirement for public health surveillance, and institutional review board (IRB) approval and patient consent were not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Data availability statement
All data were the result of secondary analyses. The majority are publicly available and cited within in the text. A small portion are not publicly available due to privacy restrictions but are available upon reasonable request to the authors.
